Compare CADL & CHSCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CADL | CHSCN |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.8M | N/A |
| IPO Year | 2021 | N/A |
| Metric | CADL | CHSCN |
|---|---|---|
| Price | $8.62 | $24.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 19.4K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $24.35 |
| 52 Week High | $9.57 | $25.78 |
| Indicator | CADL | CHSCN |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 39.58 |
| Support Level | $4.80 | $25.00 |
| Resistance Level | $9.42 | $25.37 |
| Average True Range (ATR) | 0.59 | 0.15 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 40.36 | 46.43 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).